SPONSOR

AbbVie

Total Trials

Recruiting

Phases

Phase 2, Phase 3, Phase 3, Phase 2, Phase 1

Conditions studied: Diabetic Retinopathy Migraine Hepatocellular Carcinoma Plaque Psoriasis Nasolabial Folds Idiopathic Pulmonary Fibrosis Healthy Volunteer Parkinson's Disease Ulcerative Colitis Irritable Bowel Syndrome

AbbVie is a US-based research-driven biopharmaceutical company spun off from Abbott Laboratories in 2013. The company built its early commercial foundation on adalimumab (Humira), which became the world's best-selling drug for over a decade, treating rheumatoid arthritis, plaque psoriasis, Crohn's disease, ulcerative colitis, and other immune-mediated conditions. AbbVie's clinical research now spans immunology, oncology/hematology, aesthetics, neuroscience, and eye care — driven significantly by the 2020 acquisition of Allergan.

In hematology, AbbVie's venetoclax (Venclexta) — a BCL-2 inhibitor developed with Genentech/Roche — has established itself as a cornerstone therapy in chronic lymphocytic leukemia and acute myeloid leukemia, with ongoing trials exploring combinations with targeted agents, CAR-T cells, and bispecific antibodies. The immunology pipeline post-Humira biosimilar era is focused on next-generation IL-23 inhibitors (risankizumab/Skyrizi) and JAK inhibitors (upadacitinib/Rinvoq), both of which are in Phase 3 trials across new indications including giant cell arteritis and uveitis.

AbbVie's neuroscience program includes significant investment in migraine prevention (atogepant, ubrogepant) and Parkinson's disease (levodopa-carbidopa intestinal gel continuous infusion). The aesthetics division, inherited from Allergan, runs trials on neurotoxins and dermal fillers, representing a distinct category of interventional research. AbbVie conducts trials at academic and clinical research sites globally and maintains an open innovation model through partnerships with smaller biotechs.

Frequently Asked Questions — AbbVie

What is venetoclax and for which blood cancers is AbbVie testing it?

Venetoclax (Venclexta) is a first-in-class BCL-2 inhibitor that restores programmed cell death in cancer cells that have become resistant to apoptosis. It is FDA-approved in combination with rituximab for relapsed/refractory CLL, with obinutuzumab for previously untreated CLL/SLL, and with azacitidine or decitabine for newly diagnosed AML in patients 75 years or older who cannot tolerate intensive chemotherapy. AbbVie and Genentech are jointly running Phase 3 trials testing venetoclax in additional combinations — including with ibrutinib, acalabrutinib, and CAR-T therapies — and exploring its role in other hematologic malignancies including follicular lymphoma and mantle cell lymphoma.

What immunology conditions does AbbVie study beyond rheumatoid arthritis?

AbbVie's current immunology trials extend well beyond RA. Risankizumab (Skyrizi), an IL-23p19 inhibitor, is approved and under active study in plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, with trials now expanding to ankylosing spondylitis and other spondyloarthropathies. Upadacitinib (Rinvoq), a selective JAK1 inhibitor, is approved in RA, atopic dermatitis, PsA, AS, non-radiographic axSpA, and Crohn's, with Phase 3 trials in giant cell arteritis, uveitis, and systemic lupus underway. AbbVie also has early-stage programs in systemic sclerosis and alopecia areata.

How has the Allergan acquisition changed AbbVie's clinical trial activity?

The 2020 Allergan acquisition significantly diversified AbbVie's trial portfolio beyond immunology and oncology. Allergan brought approved products in eye care (dry eye disease treatments), central nervous system (buprenorphine, muscle relaxants), aesthetics (onabotulinumtoxinA/Botox, Juvederm fillers), and women's health. Post-acquisition, AbbVie runs trials extending Botox indications (including bladder dysfunction, chronic migraine, limb spasticity), investigational eye disease therapies, and next-generation aesthetic biologics. The neuroscience portfolio now also includes CGRP receptor antagonists for migraine (atogepant) and opioid dependence programs.

Clinical Trials by AbbVie

NCT07592273 Phase 2, Phase 3

Recruiting

Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema

Diabetic Retinopathy

NCT05125302 Phase 3

Recruiting

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

Migraine

NCT06109272 Phase 2, Phase 3

Recruiting

A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

NCT07039110

Recruiting

Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Plaque Psoriasis

NCT07794878 Phase 3

Recruiting

Study to Assess Adverse Events and How Effective NOA LIFT is Compared to JUVÉDERM VOLIFT With Lidocaine for the Correction of Nasolabial Folds in Adults

Nasolabial Folds

NCT07230288 Phase 2

Recruiting

Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

NCT07649954 Phase 1

Recruiting

A Study to Evaluate How Multiple Doses of Itraconazole Interacts With Nacresertib in Healthy Adult Participants

Healthy Volunteer

NCT07219030 Phase 1

Recruiting

A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants

Healthy Volunteer

NCT07227896

Recruiting

Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease

Parkinson's Disease

NCT07071519 Phase 3

Recruiting

A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis

Ulcerative Colitis

NCT03339128 Phase 2

Recruiting

Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children

Irritable Bowel Syndrome

NCT07772492 Phase 3

Recruiting

A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata

Severe Alopecia Areata

NCT07365241 Phase 3

Recruiting

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

Small Cell Lung Cancer

NCT07222709 Phase 1

Recruiting

A Study to Assess the Adverse Events and How Oral ABBV-1042 Moves Through the Body of Healthy Adult Participants

Healthy Volunteer

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology